Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Attralus, amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 14, 2020 Category: Pharmaceuticals Source Type: news
Outcomes in Patients With Cardiac Amyloidosis and ICD Outcomes in Patients With Cardiac Amyloidosis and ICD
This study compared survival in patients with cardiac amyloidosis with and without a primary prevention implantable cardioverter-defibrillator. Did an ICD improve outcomes?Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis
A new study explores whether it is feasible to perform TAVI in patients with aortic stenosis and probable concomitant transthyretin amyloidosis.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
New York man, 52, walks again after learning back pain was a rare form of HEART DISEASE
Rick Weber, 52, from New York, learned that the pain in his back and legs was being caused by cardiac amyloidosis, abnormal protein deposits in his heart that didn't allow blood to flow properly. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2020 Category: Consumer Health News Source Type: news
New Option for AL Amyloidosis: Daratumumab Added to CyBorD New Option for AL Amyloidosis: Daratumumab Added to CyBorD
The addition of daratumumab to the standard CyBorD regimen produced ' substantial ' increases in hematologic response rates and delayed the time to organ failure.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P<0.0001]), compared to CyBorD. Additionally, treatment with D-CyBorD delayed the time ...
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
What Is the Main Cause of Amyloidosis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 5, 2020 Category: General Medicine Source Type: news
Untangling the Physiology of Transthyretin Cardiac Amyloidosis Untangling the Physiology of Transthyretin Cardiac Amyloidosis
A new study investigates echocardiographic phenotypes of transthyretin cardiac amyloidosis, the most common etiology of restrictive cardiomyopathy, identifying parameters predictive of survival.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Unbiased proteomic approach identifies pathobiological profiles in the brains of preclinical models of repetitive mild traumatic brain injury, tauopathy, and amyloidosis - Ojo JO, Crynen G, Algamal M, Vallabhaneni P, Leary P, Mouzon B, Reed JM, Mullan M, Crawford F.
No concerted investigation has been conducted to explore overlapping and distinct pathobiological mechanisms between repetitive mild traumatic brain injury (r-mTBI) and tau/amyloid proteinopathies considering the long history of association between TBI... (Source: SafetyLit)
Source: SafetyLit - April 6, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Study of rare genetic disorder that effects the eyes
(Shinshu University) Small gauge vitrectomy for vitreous amyloidosis and subsequent management of secondary glaucoma in patients with hereditary transthyretin amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2020 Category: International Medicine & Public Health Source Type: news
Drug Trial Snapshot: ONPATTRO
ONPATTRO is a drug for the treatment of nerve damage in adult patients with hereditary transthyretin-mediated amyloidosis. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 30, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Long Delays in Amyloidosis Dx, Even With Established Cardiac Care Long Delays in Amyloidosis Dx, Even With Established Cardiac Care
The underrecognized disease is rare and diagnosis complicated by a lack of awareness and heterogeneity of symptoms at presentation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news
anti-cancer drug safe and effective for treating light chain (AL) amyloidosis
(Boston University School of Medicine) There's a new treatment option available for patients with AL amyloidosis: daratumumab. Studied in a prospective clinical trial, only one of the two clinical trials of this agent in AL amyloidosis worldwide, researchers have found this anti-cancer drug to be well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2020 Category: International Medicine & Public Health Source Type: news
ASNC, ASE win CMS recognition for ImageGuide Registry
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading:
ASNC releases directive on cardiac amyloidosis imaging
Imaging groups oppose cuts in myocardial PET rates
ACC, ASE release echocardiography training guidance
ASNC names Beanlands as president (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 22, 2020 Category: Radiology Source Type: news
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
CARLSBAD, Calif., Jan. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and co... Biopharmaceuticals, Neurology, Personnel Ionis Pharmaceuticals, RNA-targeted, antisense, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 9, 2020 Category: Pharmaceuticals Source Type: news
